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Introduction
At the start of the millennium the World Health Organization 
(WHO) declared obesity a worldwide epidemic.1 From 1980 
to 2015, the largest worldwide increase in obesity prevalence 
was seen in men aged 25–29 years living in countries with a 
low-middle socio-demographic index.2 Lingering widespread 
poverty and progressive urbanization leads to low-cost, 
easily available foods, high in sugar and salt, and with little 
nutritional value. In South Africa, 42.0% of adult females, 
and 13.5% of adult males are classified as obese, the highest 
recorded numbers in Sub-Saharan Africa.3
Metabolic surgery (MS) has long been known to be 
effective in the management of weight, but has also emerged 
as effective treatment of obesity related co-morbid disease, 
decreasing mortality and the burden on Health Systems.4 
Sleeve gastrectomy (SG) and Roux-and-Y gastric bypass 
(RYGB) are emerging as the most commonly utilized 
procedures.5,6 In a joint statement by the International 
Diabetes Organizations, MS is recommended as treatment for 
Type 2 Diabetes (T2D) in patients with a Body Mass Index 
(BMI) ≥ 40 kg/m2 (class III obesity) regardless of the level of 
glucose control and patients with a BMI 35–40 kg/m2 (class 
II obesity) with poorly controlled hyperglycaemia.7 Surgery 
should also be considered in patients with poorly controlled 
hyperglycaemia, with a BMI of 30–34.9 kg/m2 (class I 
obesity). The 2017 Society for Endocrinology, Metabolism 
and Diabetes of South Africa (SEMDSA) guidelines for the 
management of T2D estimate the number of people living 
with diabetes in Africa to increase by 140% by the year 
2040, and their recommendations are in accordance with 
international guidelines.8
MS has been performed in the private sector in South 
Africa with excellent outcomes, but there are limited reports 
representing public hospitals, none of which report on 
the performance of RYGB.9-11 With an increasingly obese 
and undernourished public patient population, studies on 
outcomes after MS in government hospitals are lacking. Since 
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2011 Tygerberg Hospital has been performing RYGB in small 
volumes, but due to the alarming increase in referrals, mainly 
from endocrinologists (both public and private), a formal MS 
program has now been established. The program includes a 
dedicated multidisciplinary team (MDT), a weekly MS list, 
participation in an international database, and international 
accreditation. This is a retrospective observational report of 
our initial experience with the main aim to assess the short-




This was a retrospective review of a prospectively maintained 
database of MS procedures performed at a single Tertiary 
Academic Centre, between 1 October 2011 to 31 September 
2017. The regional Health Research Ethics Committee 
approved the protocol (S16/08/157). 
Participants were considered for the MS program according 
to guideline recommendations, where MS is indicated in adult 
patients with a BMI ≥ 35 kg/m2 and an associated obesity 
related comorbid disease, or patients with a BMI ≥ 40 kg/
m2, without any obesity related comorbid disease, and where 
lifestyle modification proved unsuccessful.12 Participants were 
excluded from undergoing MS in the following instances; 
age < 20 years or > 60 years, current smoking or excessive 
previous or current alcohol or drug use/abuse, uncontrolled 
psychiatric illness, immobility or concurrent co-morbidity 
deemed too high anaesthetic risk (if evaluated as such by a 
specialist anaesthesiologist), contra-indication to laparoscopic 
surgery (inability to undergo general anaesthetic or multiple 
previous open abdominal surgeries), active underlying bowel 
disease (malignancy or inflammatory bowel disease), lack of 
commitment or resources with regards to the short, medium 
and long term adherence to follow-up and surveillance, and 
lastly, planned pregnancy in the two years following surgery.
Procedures
All patients underwent education regarding the MS program, 
were referred for psychiatric evaluation and attended two 
dietitian group sessions. If there was concern for the presence 
of an uncontrolled comorbid metabolic condition, evaluation 
by the endocrinologist was completed. Preoperative nutritional 
deficiencies were assessed and managed by the treating 
endocrinologist. Preoperative investigations included basic 
blood tests, a chest radiograph, abdominal sonography, and a 
gastroscopy, and all patients followed a 2-week preoperative 
low-calorie liquid diet. 
RYGB was offered to all patients, with SG reserved for cases 
in which intraoperative assessment judged the performance of 
a RYGB as unsafe. All surgical procedures were performed 
according to a standardised technique, and in most cases 
in the presence of a South African Society for Obesity and 
Metabolism (SASOM) proctor. Postoperatively patients were 
accommodated in a ward (surgical, anaesthetic or medical) 
with at least high care monitoring capabilities for 24 hours, 
and discharge home was aimed for within 3 days. Plasma 
glucose was monitored intra- and postoperatively according 
to standard hospital protocol. Patients were discharged 
on a vitamin/mineral replacement regime available in the 
public sector and in accordance with post-metabolic surgery 
needs.13 Lifelong daily proton pump inhibitor (PPI) therapy 
(lansoprazole 30 mg orally daily) was prescribed, and for the 
first two weeks after surgery patients were provided with low 
molecular weight heparin (enoxaparin 60 mg subcutaneously 
daily).
Patients were followed up at the endocrinologist run 
metabolic surgery clinic at 2 weeks, 3 months, 6 months, 
and thereafter annually. Postoperative endocrine surveillance 
included a proactive approach with regards to the expected 
micro and macronutrient deficiencies according to Endocrine 
Society Practice guidelines.13 Postoperative endoscopy was 
performed on indication in symptomatic patients only. 
Baseline data collected included demographics, weight, 
BMI, and the presence of comorbid disease. Secondary 
outcomes included procedural details (procedure performed, 
conversion to open surgery, operating time, intraoperative 
blood loss, postoperative ward, and length of postoperative 
hospital stay), and effect of surgery on weight and T2D status, 
as well as micronutrient status at follow-up. The primary 
outcome was safety, including mortality, and intraoperative 
events, and early and late postoperative adverse events.
Definitions
Follow-up, comorbid disease, weight loss, diabetes resolution, 
and adverse events were defined according to the American 
Society for Metabolic and Bariatric Surgery (ASMBS) 
outcome reporting standards.14 Follow-up was defined as 
recent (< 6m), very short-term (6m–1yr), short-term (1yr–
3yrs), medium term (3yrs–5yrs), and long-term (> 5yrs). 
T2D was defined as a serum HbA1c > 6.5% or fasting 
glucose > 7 mmol/L at two occasions, or a known diagnosis 
of T2D on treatment. Stage 1 and 2 hypertension were defined 
as a blood pressure of 140-159/90-99 mmHg or >160/>100 
mmHg respectively. Borderline dyslipidaemia was defined 
as LDL cholesterol 3.4–4.1 mmol/L, total cholesterol 5.2–
6.2 mmol/L, and triglycerides 1.7–2.3 mmol/L. Confirmed 
dyslipidaemia was defined as LDL cholesterol > 4.1 mmol/L, 
total cholesterol > 6.2 mmol/L, and triglycerides > 2.3 
mmol/L. Obstructive sleep apnoea (OSA) was confirmed in 
cases where an overnight sleep polysomnography test resulted 
in an Apnoea-Hypopnea Index (AHI) of  > 5 events per hour, 
and it was suspected in patients with an Epworth Sleepiness 
Scale (ESS) score of more than 12.
Operative weight was defined as the patient’s weight as 
measured closest to the time of surgery. Weight loss was 
measured in terms of percent total weight loss (%TWL) 
and percent excess BMI loss (%EBMIL). Percent TWL 
was calculated as %TWL = [(operative weight) – (follow-
up weight)]/[(operative weight)] x 100, and %EBMIL was 
calculated as %EBMIL = [(operative BMI)-(follow-up BMI)]/
[(operative BMI)-25] x 100. Complete remission of T2D was 
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defined as normal measures of glucose metabolism (HbA1c < 
6% and fasting blood glucose < 5.6 mmol/L) in the absence of 
antidiabetic medications. 
Adverse events were classified as intraoperative events, 
and early (< 30 days) and late (> 30 days) postoperative 
adverse events. Intraoperative events included any eventuality 
(surgical and non-surgical) that resulted in deviation from the 
standard theatre procedure. Postoperative adverse events were 
defined as major if they resulted in prolonged hospital stay 
(> 7 days), or if anticoagulant therapy, re-intervention or re-
operation was needed. 
Statistical analyses
Statistical analyses were performed with SPSS version 24 
for Mac. Descriptive statistics were used and reported as 
number of patients and percentage of the cohort for discreet 
values, whereas continuous variables were expressed as mean 
(standard deviation), with ranges supplied when applicable. 
Changes in weight were analysed using a paired t-tests, and 
for comparisons of pre- and postoperative diabetes status, 
McNemar’s was used, and a p-value < 0.05 considered as 
significant.
Results
Over a 6 year period, a total of 57 patients underwent MS at 
Tygerberg Hospital, with 28 (49.1%) of these performed in 
the most recent 12 months (Table 1). One patient 
was lost to follow-up 2 years after surgery, resulting 
in a 1-year postoperative follow-up rate of 100%. 
The baseline characteristics and procedural details 
are presented in Table 2. Ninety seven percent of 
patients were diagnosed with class III obesity, and 
84% of patients were classified as super obese (BMI 
≥ 50 kg/m2). For the initial 24 hours postoperatively, 
49.1% of patients were treated in a high care unit 
(surgical or anaesthetic), and 50.9% of patients in the 
surgical intensive care unit (ICU). All patients were 
transferred to a general surgical ward after 24 hours. 
Discharge by postoperative day 3 was achieved in 21 
(36.8%) of patients.
Table 3 and Figure 1 represent changes in weight 
1 year postoperatively. A complete remission of 
T2D was observed in 15 patients (62.5%), with a 
statistically significant reduction from 24 patients 
(42.1%) with T2D at baseline, to 9 patients (17.3%) 
with T2D at 1 year follow-up (P = 0.0003). Thirteen patients 
with T2D (54.2%) could stop all of their antidiabetic 
medication, and a further 4 patients (16.7%) could decrease the 
number of medications needed for glucose control. Vitamin 
B12 deficiency was present in 3.5% (n=52) of patients at 
1-year follow-up, with Vitamin D deficiency present in 52.6% 
(n= 41) of patients. Iron, folate, and calcium deficiencies were 
present in 21.1% (n=40), 12.3% (n=39), and 15.8% (n=54) of 
patients respectively.
There were no deaths recorded, and overall morbidity was 
14.0% (Table 4). Surgical intraoperative events included 
bleeding (splenic ooze and port-site bleed), iatrogenic 
serosal bowel injury (stomach remnant and small bowel), 
solid organ injury (pancreas laceration and liver subcapsular 
hematoma), one stapler misfire, and blue dye leak during 
testing in 7 patients (12.3%). All of these events were 
noticed immediately and could be dealt with during the same 
anaesthesia. In one patient postoperative apnoea occurred 
minutes after extubation, necessitating re-intubation and 
overnight ventilation. Three major adverse events (5.3%) 
were recorded, accounting for all the readmissions in this 
series, with no patients requiring reoperation. Two patients 
developed deep vein thrombosis (DVT), 2 months and 2 years 
after surgery respectively, both treated with anticoagulation. 
A further patient was re-admitted 2 weeks postoperatively 
with sepsis, dehydration and renal failure, and a diagnosis 
of emphysematous pyelonephritis (secondary to a stag-horn 
Table 1. Follow-up rate during the study period 
Follow-up rate (N=57)
Time after surgery Patients operated n (%) Eligible patients Patients who presented Follow-up rate (%)
< 6 months 21 (36.8%) 57 57 100%
6 months – 1 year 7 (12.3%) 36 36 100%
1 year – 3 years 17 (29.8%) 29 28 96.6%
3 years – 5 years 9 (16.1%) 12 11 91.7%
> 5 years 3 (5.4%) 3 2 66.7%
Figure 1. Change in weight 1 year post-operatively. Error bars 
represent 95% Confidence Intervals. %TWL = Percentage Total Weight 
Loss, %EBMIL = Percentage Excess Body Mass Index Loss.
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kidney stone) was made, and treated successfully with JJ-
stent placement and intravenous antibiotics. Minor adverse 
events (8.8%) included lignocaine infusion toxicity (n=1), 
gastroparesis (n=1), wound sepsis (n=1), and dumping 
syndrome (n=2). One patient developed postoperative 
dysphagia, and one complained of regurgitation, but in both 
cases endoscopy and contrast swallows were normal. A 
further six patients underwent postoperative gastroscopy for 
heartburn. There was no evidence of esophagitis, marginal 
ulceration or anastomotic strictures reported, but in one 
patient Barret’s oesophagus changes were confirmed.
Table 2. Baseline characteristics and procedural details
Patient characteristic (N=57)
n (%) or mean (SD) 
[range]
   Age (years) 42.8 (8.0) [23-58]
   Female sex 44 (83.0)
   Weight (kg) 156.3 (32.7) [91-242]
   BMI (kg/m2 ) 58.8 (10.7) [37-83]
      < 35 0
      35-39.9 2 (3.5)
      40-49.9 7 (12.3)
      50-59.9 21 (36.9)
      60-69.9 17 (29.8)
      70-79.9 7 (12.3)
      ≥ 80 3 (5.3)
   Diabetes
      No diabetes 33 (57.9)
      Diabetes 24 (42.1)
   Hypertension
      No hypertension 23 (40.4)
      Stage 1 hypertension 19 (33.3)
      Stage 2 hypertension 15 (26.3)
   Dyslipidaemia
      No dyslipidaemia 34 (59.7)
      Borderline dyslipidaemia 2 (3.5)
      Confirmed dyslipidaemia 21 (36.8)
   OSA
      No OSA 28 (49.1)
      Confirmed testing – no treatment 3 (5.3)
      Confirmed testing – home CPAP 8 (14.0)
 Suspected symptoms 
            – no treatment 18 (31.6)
   GERD
      No GERD symptoms and normal 
     gastroscopy 23 (40.4)
      GERD confirmed on gastroscopy 34 (59.6)
Procedural details
   Procedure
       SG without cholecystectomy 1 (1.8)
       RYGB with cholecystectomy 11 (19.3)
       RYGB without cholecystectomy 45 (78.9)
   Operating time (min) 185.0 (48.5) [95-330]
   Blood loss (ml) 66.1 (65.4) [10-250]
   Conversions to open 0 (0)
   Postoperative ward
      High care ward 28 (49.1)
      Intensive care unit 29 (50.9)
   Postoperative hospital stay (days) 3.9 (1.1) [3-7]
SD = Standard Deviation, BMI = Body mass Index, OSA = Obstructive 
Sleep Apnoea, CPAP = Continuous Positive Airway Pressure, GERD = 
Gastro Esophageal Reflux Disease, SG = Sleeve Gastrectomy, RYGB = 
Roux and Y
Table 3. Change in weight at 1 year (N=39)
Mean (SD, 95%CI)
Δ Weight (kg) 44.4 (18.1, 37.4–51.3)
Δ BMI (kg/m2 ) 16.4 (6.2, 13.9–18.9)
%TWL 27.6 (8.1, 24.3–30.9)
%EBMIL 50.4 (15.8, 44.0–56.8)
SD = Standard Deviation, CI = Confidence Interval, BMI = Body Mass 
Index, %TWL = Percentage Total Weight Loss, %EBMIL = Percentage 
Excess Body Mass Index Loss
Table 4. Adverese events
Event (N=57) n (%)
Intra-operative events 15 (26.3)
     Surgical 14 (24.6)
          Bleeding 2 (3.5)
          Bowel injury 2 (3.5)
          Solid organ injury 2 (3.5)
          Stapler misfire 1(1.8)
          Blue dye leak 7 (12.3)
     Non-surgical 1 (1.8)
          Postoperative apnoea 1 (1.8)
Adverse events 8 (14.0)
     Major 3 (5.3)
          Early (< 30 days) major A/E 1 (1.8)
          Late (> 30 days) major A/E 2 (3.5)
     Minor 5 (8.8)
          Early (< 30 days) minor A/E 3 (5.3)
          Late (> 30 days) minor A/E 2 (3.5)
Mortality 0 (0)
Others 
     Postoperative dysphagia 1 (1.8)
     Postoperative regurgitation 1 (1.8)
     GERD symptoms present 6 (10.5)
     GERD confirmed on gastroscopy 1 (1.8)
A/E = Adverse event, GERD = Gastro-Esophageal Reflux Disease
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Discussion
This report, with short-term follow-up (79% < 3 years), 
confirms that RYGB can be performed safely in a government 
hospital setting in South Africa, with mortality (0%) and 
morbidity (14%) rates comparable to international outcomes. 
The predominantly middle aged female patient cohort, with 
a mean BMI of 59 kg/m2 and 42.1% of patients known 
with T2D, is comparable to both national and international 
patient populations undergoing MS.9-11 The mean BMI of our 
initial experience leans towards the higher end of the scale 
when compared to most series, and this is likely reflected 
in the reported operating time of 185 minutes. When at the 
beginning of the learning curve, it is prudent to select patients 
with a lower BMI in order to minimise perioperative risk.
The current study is the only report on RYGB performed in 
a government setting in South Africa, and provides a detailed 
description of intraoperative events that might be expected 
when performing MS. There were no conversions to open 
surgery, and all events were immediately recognised, with no 
need for reoperation or known long-term consequences for 
the patient. Major morbidity after MS has fallen from 5% in 
older large database reports, to 3% more recently.15,16 In our 
series we had no anastomotic leaks, but worldwide the risk 
remains at 0.09% in randomised controlled trials, and 1.14% 
in observational studies.17 Our major and minor morbidity 
rate of 5.3% and 8.8% respectively also compares well to the 
limited national numbers available.9-11 In the current series, 
where postoperative endoscopy is performed on indication in 
symptomatic patients only, no marginal ulceration was noted 
at follow-up. Due to initial reports of marginal ulceration in 
up to 16% of patients undergoing RYGB, and due to a paucity 
in studies regarding ideal duration of treatment at the time, we 
placed all patients on lifelong PPI therapy.18 There is ongoing 
debate surrounding the optimal duration of treatment, but 
recent evidence suggests that a 90-day regimen is superior 
to a 30-day regimen, and we have adjusted our practice 
accordingly.19 
OSA was present in 50.9% of patients, mostly diagnosed 
based on symptomatology scoring, and most patients did 
not have preoperative home treatment. One patient required 
overnight ventilation due to postoperative apnoea. Recent 
recommendations include the use of the STOP-Bang score 
in conjunction with saturation monitoring  as screening 
tool for OSA, and we are adjusting accordingly.20 Due to 
the low volume of metabolic procedures at our centre, 
and the often overloaded and understaffed surgical wards, 
patients were treated in a high-care or ICU for the first 24 
hours postoperatively. The demand for high care beds in an 
academic centre, coupled with the fact that apnoea monitoring 
and early mobilization form the cornerstone of immediate 
postoperative care in patients undergoing MS, will lead to 
innovative postoperative care strategies over time, helping to 
formulate future guidelines. 
With the exception of a single patient undergoing SG, all 
patients had a RYGB performed, and 19.3% of these were 
accompanied by a cholecystectomy. The SG was decided on in 
a patient with a BMI of 83 kg/m2, where after port placement 
and liver retraction, limited space and concern for Roux limb 
reach, suggested a SG to be a safer procedure. At the start of 
our program, all patients underwent preoperative abdominal 
ultrasonography, and cholecystectomy was performed for 
the presence of gallstones.21 Although controversial due to 
a reported incidence of postoperative cholelithiasis in up to 
38% of patients, we currently follow a conservative approach 
to asymptomatic gallstone disease.22-24 In patients with 
symptomatic gallstones a staged approach is followed due to 
the increased risk of perioperative complications associated 
with concomitant cholecystectomy.25 Should patients 
develop postoperative choledocholithiasis, laparoscopic 
assisted endoscopic retrograde cholangiography (ERCP) is 
considered.26
Total weight loss 2–3 years after RYGB ranges between 
25.5% and 33.3% in randomised controlled trials (RCT), 
and our number of 27.6% also compares well to local reports 
of 29.1%.9,27,28 Complete remission of T2D can be expected 
in 78% of diabetics after MS, and 62.5% of diabetics in the 
current report attained this goal.29 Reports on T2D remission 
rates 10 years after MS indicate a fall from 70% to 40%, 
especially in patients with diabetes duration of longer than 4 
years at the time of operation.30 Pre-existing malnutrition in 
obese individuals can be exacerbated after MS. The number 
of patients with postoperative micronutrient deficiencies 
in our cohort is well below the prevalence of pre-existing 
(preoperative) micronutrient deficiencies reported in the 
literature, but it remains a concern in patients with perceived 
limited resources.31 Preoperative patient screening is a major 
contributor to acceptable longer-term outcomes, and large-
scale prospective studies are needed to answer questions 
regarding eligibility criteria for the South African public 
patient population.
Limitations of the current study include the low volume of 
patients reported on, as well as the retrospective nature, relying 
on accurate database entry. Longer-term adverse events 
such as internal herniation, stomal ulceration and stenosis, 
and micronutrient deficiencies, especially of concern after 
RYGB, remain potential risks in a patient population where 
both immediate and long-term access to health care might be 
challenging.32,33 With reference to the Core Outcome Set for 
the Benefits and Adverse Events of Bariatric and Metabolic 
Surgery (The BARIACT Project), a further limitation of this 
study is the absence of data on overall quality of life and 
cardiovascular risk.34
The mortality after MS has in recent years fallen from 2% 
to 0.3%, and our results prove that it can be performed safely 
in a government hospital in South Africa.35 High volume 
accredited centres and national registries do provide better 
outcomes, underlining the need for metabolic centres in South 
African academic hospitals.36-38 The unique financial, patient 
volume, and resource restrictions of public health care in 
South Africa means that we will have to define the future role 
of MS in the public sector, while ensuring that this treatment 
option remains available to all patients.
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Conclusion
This report is the first to confirm that Roux-and-Y gastric 
bypass can be performed safely in an academic hospital in 
South Africa. As outcomes are closely related to both surgeon 
and centre volume, larger scale studies are needed to answer 
questions regarding long-term safety and cost-effectiveness.
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